Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAAs, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAAs or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAAs, providing assistance for a fruitful use of HCV resistance testing in clinical practice.

Sorbo, M.C., Cento, V., Di Maio, V.C., Howe, A., Garcia, F., Perno, C.F., et al. (2018). Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. DRUG RESISTANCE UPDATES [10.1016/j.drup.2018.01.004].

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018

Di Maio V. C.;Ceccherini-Silberstein F.
2018

Abstract

Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAAs, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAAs or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAAs, providing assistance for a fruitful use of HCV resistance testing in clinical practice.
Online ahead of print
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - Microbiologia e Microbiologia Clinica
eng
Con Impact Factor ISI
Direct acting antiviral agents; Fold-change; HCV genotypic resistance testing; HCV sequencing; Treatment failure
Sorbo, M.C., Cento, V., Di Maio, V.C., Howe, A., Garcia, F., Perno, C.F., et al. (2018). Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. DRUG RESISTANCE UPDATES [10.1016/j.drup.2018.01.004].
Sorbo, Mc; Cento, V; Di Maio, Vc; Howe, Aym; Garcia, F; Perno, Cf; Ceccherini-Silberstein, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Sorboetal2018.pdf

non disponibili

Licenza: Non specificato
Dimensione 5.07 MB
Formato Adobe PDF
5.07 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/195078
Citazioni
  • ???jsp.display-item.citation.pmc??? 55
  • Scopus 131
  • ???jsp.display-item.citation.isi??? 121
social impact